The authors randomly assigned 40 older adults with symptomatic peripheral arterial disease to ramipril, 10 mg/d, or to placebo.
After adjustment for between-group baseline differences, mean pain-free walking time after ramipril treatment was 227 seconds
(95% CI, 175 seconds to 278 seconds; P < 0.001) longer than after placebo treatment. Similarly, maximum walking time improved by 451 seconds in the ramipril group
(CI, 367 seconds to 536 seconds; P < 0.001) but did not change in the placebo group. No adverse events were reported.